Full Press Release Details
Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.
Pursuant to Belgian transparency legislation1, Lakefront received a transparency notification from Madison Avenue Partners on June 24, 2026. The notification indicates that Madison Avenue Partners, LP, jointly with Madison Avenue International, LP, EMAI Management, LLC, and Eli Samaha, crossed above the threshold of 5% of Lakefront’ voting rights on an aggregated basis on June 15, 2026, following the acquisition of Lakefront’ voting rights.
On June 24, 2026, Madison Avenue Partners (taking into account the holding of its affiliates) owned 3,498,892 voting rights, representing 5.31% of Lakefront’ currently outstanding 65,897,071 shares.
Summary of the transaction:
| Date on which the threshold was crossed | Date of notification | Direct voting rights after the transaction | Equivalent financial instruments after the transaction | Total (%)voting rights |
| June 15, 2026 | June 24, 2026 | 3,498,892 | 0.00% | 5.31% |
Content of the notification from Madison Avenue Partners:The notification dated June 24, 2026, contains the following information:• Date of notification: June 24, 2026• Date on which the threshold is crossed: June 15, 2026• Threshold of voting rights crossed (in %): 5%• Notification by: Madison Avenue Partners• Denominator: 65,897,071• Reason for the notification: Acquisition or disposal of voting securities or voting rights• Notified details:
| A) Voting Rights | Previous notification | After the transaction | |||
| # of voting rights | # of voting rights | % of voting rights | |||
| Holder of voting rights | Linked to securities | Not linked to securities | Linked to securities | Not linked to securities | |
| Madison Avenue Partners, LP | 0 | 3,498,892 | 5.31% |
| B) Equivalent financial instruments | After the transaction | |||||
| Holder of equivalent financial instruments | Type of financial instrument | Expiration date | Exercise period or date | # of voting rights that may be acquired if the instrument is exercised | % of voting rights | Settlement |
| TOTAL | 0 | 0.00% |
| TOTAL (A&B) | # of voting rights | % of voting rights |
| 3,498,892 | 5.31% |
The chain of control has been described at the end of the notification (section 11) and can be foundhere.
About Lakefront®BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visithttps://www.lakefrontbio.comor follow us onLinkedInorX.
For further information, contact Lakefront Biotherapeutics:Investor RelationsSherri Spear+1 412 522 6418sherri.spear@lakefrontbio.com
1Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.